NICE Rejection Of Celgene's Otezla Finalized; Four JIA Drugs Reviewed
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has issued final guidance not recommending Celgene's psoriatic arthritis drug Otezla (apremilast) for use on the National Health Service; but the committee has given the nod to four products for the treatment of juvenile idiopathic arthritis.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.